Is the Indian version of midostaurin reliable? Are the effects of generic drugs significantly different from those of original drugs?

Midostaurin As an oral multi-target kinase inhibitor for the treatment of FLT3 mutant acute myeloid leukemia (AML) and systemic mastocytosis (SM), it has gradually occupied an important position in international clinical treatment in recent years. Since the original version of the drug has not yet been officially launched in mainland China, is expensive and has limited access, many patients have turned their attention to original and generic versions of the drug overseas, especially in the Indian market. Currently, original drugs (such as the version produced under license from Novartis) and multiple reliable generic drug brands (such as BDR, etc.) have been introduced into the Indian market, becoming one of the alternatives for patients.

In terms of efficacy, Indian generic versions of midostaurin are produced in strict accordance with internationally accepted generic drug standards, which means that they must pass bioequivalence evaluation to prove that their absorption rate and extent in the human body are basically the same as the original drugs. The relevant drug regulatory agencies in India have relatively strict standards for generic oncology drugs, especially pharmaceutical companies such asBDR and Zydus, which have high international reputation and have exported their products to many countries. There is no significant difference between generic drugs and the original drugs in terms of dosage specifications (such as 25mg*28 tablets), active ingredients, and indications. In theory, they can provide similar therapeutic effects to the original drugs, and they also show high consistency in actual clinical feedback.

Of course, patients still need to pay attention to the formality of the source of the drug when choosing generic drugs. Products with formal packaging, batch numbers and English instructions should be purchased through reliable channels to avoid purchasing counterfeit drugs or inferior products that may affect the therapeutic effect.

Generally speaking, the quality of the Indian version of midostaurin, whether it is original or generic, is mostly guaranteed, especially in terms of price. The original version is priced at about 5,000 yuan per box, while the generic version may be around 3,000 yuan (the price may fluctuate due to exchange rates), which effectively alleviates economic pressure.

Reference materials:https://medlineplus.gov/druginfo/meds/a617033.html